Dr. Qiu Lugui

Dr. Qui Lingui has dedicated over 30 years to clinical and basic research on hematological diseases and is recognized as a leading academic figure in the field of lymphoma treatment in China. His primary research focuses on the molecular pathogenesis and effective treatment strategies for tumors of the lymphatic system, as well as the clinical and related foundations of hematopoietic stem cell transplantation.

He excels in the precise diagnosis, treatment, and translational research of lymphoid tumors such as lymphoma and multiple myeloma, and is one of the main academic leaders in the field of lymphoid system tumors in China.

Dr. Qiu Lugui is a distinguished expert specializing in the diagnosis and treatment of hematologic malignancies. His primary areas of expertise include:

1. Acute Leukemia: Dr. Qiu Lugui has extensive experience in the diagnosis and management of acute leukemia, including both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
2. Chronic Leukemia: He is proficient in treating chronic leukemia cases, particularly chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
3. Myelodysplastic Syndromes (MDS): His specialization also covers the diagnosis and treatment of MDS, a group of disorders caused by poorly formed or dysfunctional blood cells.
4. Lymphoma: Dr. Qiu is an expert in the comprehensive management of various types of lymphoma, applying advanced therapeutic protocols.
5. Multiple Myeloma: He offers specialized treatment plans for multiple myeloma, focusing on personalized and targeted therapies.
6. Hematopoietic Stem Cell Transplantation: His expertise includes performing stem cell transplants and providing curative options for patients with hematologic malignancies.

Dr. Qiu Lugui’s dedication to advancing hematology through clinical practice and research has earned him recognition as a leading figure in the field.

Dr. Qiu Lugui offers a comprehensive range of treatments for hematologic malignancies. His expertise encompasses the following treatments:

1. CAR T-Cell Therapy: Specializes in Chimeric Antigen Receptor (CAR) T-cell therapy, an innovative immunotherapy that harnesses the power of a patient’s immune cells to target and destroy cancer cells, particularly for relapsed or refractory leukemia and lymphoma.
2. Chemotherapy: Administers tailored chemotherapy regimens for acute and chronic leukemia, lymphoma, and multiple myeloma.
3. Targeted Therapy: Utilizes targeted drugs to treat specific genetic mutations in leukemia and other blood cancers, enhancing treatment efficacy with fewer side effects.
4. Immunotherapy: Offers advanced immunotherapies, including monoclonal antibodies and immune checkpoint inhibitors, to boost the body’s immune response against cancer.
5. Hematopoietic Stem Cell Transplantation (HSCT): Specializes in autologous and allogeneic stem cell transplantation to treat leukemia, lymphoma, and myelodysplastic syndromes (MDS).
6. Precision Medicine: Develops personalized treatment plans based on genetic and molecular diagnostics to improve patient outcomes.
7. Supportive Care: Provides comprehensive supportive care, including infection management, transfusions, and symptom control during and after treatment.
8. Clinical Trial Access: Facilitates patient participation in cutting-edge clinical trials, offering access to novel therapies and investigational drugs.

Dr. Qiu Lugui’s multidisciplinary approach and expertise in cutting-edge therapies like CAR T-cell therapy ensure that each patient receives the most effective and personalized treatment for their condition.

Dr Qui Lingui has published more than 400 research papers in important professional journals at home and abroad, including more than 130 SCI papers and more than 120 reviews/monographs. He has edited 4 monographs and participated in the writing of more than 10 monographs.